Home » Newsletters » BioWorld Science

BioWorld Science

May 21, 2013

View Archived Issues

A groundbreaking technique to aid accurate network imaging in intact brains

Dual mTORC1/2 inhibitor shows promise as immunosuppressant in vivo

The development of probes to determine the therapeutic potential of epigenetic inhibitors

Clinical results presented for a novel cancer immunotherapy

Phase IIa studies indicate GFT-505 may reduce remnant cholesterol

Helsinn and Vifor sign agreement for netupitant/palonosetron fixed-dose combination

Bayer seeks approval for riociguat in Japan

AbbVie and Galapagos add Crohn's disease to GLPG-0634 collaboration

Novo Nordisk reports results from first phase III trial of N9-GP

FDA clears Oramed's IND to test ORMD-0801 oral insulin

Otsuka reports on regulatory and clinical developments of fiscal 2012

Curie-Cancer and Roche partner further on translational research programs

Sanofi reports topline data from pivotal phase III JAKARTA study

XenoPort ends development of arbaclofen placarbil for MS spasticity

Bydureon launched in Japan

Breakthrough therapy designation for Synageva's sebelipase alfa

Astex Therapeutics designs novel FGFR inhibitors

Scientists at GlaxoSmithKline present new agents for cancer

FDA grants orphan drug status to ibrutinib, terguride and HIRMAb-IDS

New mTOR inhibitors disclosed by Novartis

Novel cannabinoid CB2 receptor agonists synthesized at Roche

Pfizer ends phase III trial of inotuzumab ozogamicin

Sanofi divulges novel PKC-beta 2 inhibitors

FDA advisory committee sets date to review MoxDuo NDA

Reva Medical offers update on development of ReZolve and ReZolve2 scaffolds

High efficacy and long duration of a new formulation of NAG-MLP and chol-siRNAs

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 8, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ASH 2025: New blood cancer therapies trump chemo, older drugs
BioWorld
Targeted therapies and immunotherapies continue to show better results than chemotherapy in investigator-initiated and company-sponsored cancer trials, and newer...